GPA hFc Chimera, Mouse
GPA HFc Chimera, Mouse

The purity of GPA hFc Chimera, Mouse is greater than 95% as determined by SEC-HPLC.

GPA HFc Chimera, Mouse

GPA hFc Chimera, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

GPA hFc Chimera, Mouse

Granulomatosis with polyangiitis (GPA) presents a wide spectrum of manifestations from the common respiratory symptoms to infrequent neurological and cardiac complications. The challenge in diagnosis and management makes the rapidly progressive disorder one of the most challenging dilemmas in clinical medicine.The ultimate goal is an improved prognosis through outcome measures which assesses the disease control with minimal adverse effects of intensive immunosuppressive regimens, an integral part of the clinical approach to improve the quality of life of GPA patients.
Z06154
¥63,425.00

Ask us a question
Product Introduction
Species Mouse
Protein Construction
GPA (Met1-Val108)_x000D_
Accession # P14220		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 38.1 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 68-75 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • GPA HFc Chimera, Mouse
    • GPA HFc Chimera, Mouse

    The purity of GPA hFc Chimera, Mouse is greater than 95% as determined by SEC-HPLC.

  • GPA HFc Chimera, Mouse
    • GPA HFc Chimera, Mouse

    GPA hFc Chimera, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Granulomatosis with polyangiitis (GPA) presents a wide spectrum of manifestations from the common respiratory symptoms to infrequent neurological and cardiac complications. The challenge in diagnosis and management makes the rapidly progressive disorder one of the most challenging dilemmas in clinical medicine.The ultimate goal is an improved prognosis through outcome measures which assesses the disease control with minimal adverse effects of intensive immunosuppressive regimens, an integral part of the clinical approach to improve the quality of life of GPA patients.
Synonyms Glycophorin-A; Glycophorin A; PAS-2; CD235a; GPA; GPErik; GpMiIII; GPSAT; GYPA; HGpMiIII; HGpMiV; HGpMiX; HGpMiXI; HGpSta(C); MNS; CD235a; MN

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.